Next Investors logo grey

Cogstate contracts provide fiscal 2019 foundation

Published 14-AUG-2018 10:17 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Name: Cogstate Ltd (ASX:CGS)

Market Capitalisation: $58 million

Opening Share Price: 55 cents

In fiscal 2018, Cogstate signed $36.1 million of new sales contracts, a 22% increase from the prior year.

Having recognised $28.1 million of revenue from those contracts, as at June 30, 2018 Cogstate had $34.8 million of contracted revenue expected to be recognised in future periods.

It is this strong revenue predictability along with the Cogstate’s anticipated near term transition to profitability that is generating interest in the company.

The company’s shares traded as high as 58 cents following the release of its result, representing an increase of 14%.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

With many small biotech companies struggling to generate revenues let alone earnings, this is a company that has set itself apart from its peers.

Cogstate entered into contracts for the license of Cognigram technology during the 2018 financial year.

Mostly the licence period was 12 months, although some contracts were for an extended period, the longest being six years.

In total, contracts to the value of $676,970 were executed during the 2018 financial year.

The other promising news looking towards fiscal 2019 is that management believes the company will transition to profitability in the second half as the full benefit of cost reduction measures is realised.

This is a speculative belief at this stage and investors should seek professional financial advice if considering this stock for their portfolio.

Diversified player in mental health sector

Cogstate also operates in a niche market, and with its expertise in cognitive conditions and technologies the company is well-positioned to take advantage of increased investment in improving mental health diagnostics, treatment and care.

Solutions provided by the company assist in optimising the measurement of cognition in clinical trials, academic research and healthcare.

Cogstate provides enabling technologies and professional services for higher quality neuropsychological assessments and it is a pioneer in commercializing rapid, reliable and highly sensitive computerized cognitive tests.

The company’s customers include the world’s leading biopharmaceutical companies, elite sporting organizations and defence forces.

On the medical front, the company is involved with physicians and patients, as well as academic institutions and public-private partnerships.

Alzheimers is a key focus area

In the last 12 months, Cogstate has continued its growth in the clinical trials market, with contract sales up 22%.

The company has also added important scientific resources, with a business development focus and expertise in key focus areas, such as Alzheimer’s disease as well as paediatric and rare diseases.

Management highlighted that a recent analysis had showed that the number of drugs in phase 2 Alzheimer’s disease studies had increased 17% over the last year.

Further, the number of disease modifying drugs in phase 2 Alzheimer’s disease studies is up 34% over the last year.

Cogstate is of the view that the huge societal need (and associated commercial opportunity) for Alzheimer’s disease treatments will result in continued investment in potential treatments.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.